CCL18 has been shown to promote immunosuppressive states and progression in esophageal squamous cell carcinoma (23), multiple myeloma (24), osteosarcoma (25), ovarian cancer (26), and renal cell carcinoma (27). Here, CCL18 is linked to ovarian cancer.